Column Group III Gp, LP sold $3.0M of TNYA
owner at Tenaya Therapeutics, Inc.. 4,400,290 shares at an average of $0.69, traded Feb 10, 2026, filed Feb 12, 2026.
Score components
- +12Role10% owner
- +25Trade size$3.0M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- +10Role exitThe filing reports the insider leaving
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +24.6%, 3m +36.7%, 6m +7.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-049028, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 10, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -161,422 | $0.82 | $132k | 4,253,298 | Feb 12, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -182,295 | $0.82 | $149k | 4,803,275 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -1,905,115 | $0.68 | $1.3M | 2,348,183 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -2,151,458 | $0.68 | $1.5M | 2,651,817 | Feb 12, 2026 |
Related signals
Other insiders at Tenaya Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $2,690 3,390 shares | -1% | |
| 23Weak | Tenaya Therapeutics, Inc. | Tomohiro Higa SVP, Finance | $1,178 1,485 shares | -1% | |
| 72Notable | Tenaya Therapeutics, Inc. | Column Group III Gp, LP owner | $2.4M 4,170,266 shares | -213% | |
| 55Moderate | Tenaya Therapeutics, Inc. | Column Group III Gp, LP owner | $505k 829,734 shares | -35% | |
| 40Moderate | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $9,557 14,862 shares | -3% | |
| 30Weak | Tenaya Therapeutics, Inc. | Tomohiro Higa SVP, Finance | $2,231 3,469 shares | -3% | |
| 30Weak | Tenaya Therapeutics, Inc. | Whittemore Tingley Chief Medical Officer | $3,319 5,160 shares | -2% | |
| 40Moderate | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $4,158 3,126 shares | -1% | |
| 30Weak | Tenaya Therapeutics, Inc. | Tomohiro Higa SVP, Finance | $1,818 1,367 shares | -1% | |
| 30Weak | Tenaya Therapeutics, Inc. | Whittemore Tingley Chief Medical Officer | $3,826 2,877 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.